Severe Atopic Dermatitis
Adbry autoinjector for atopic dermatitis now available in US
Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.
Oral Systemic Therapy
Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis
Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.
Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Amlitelimab maintains patient response in atopic dermatitis following treatment cessation
Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.
FDA clears investigational new drug application for ICP-332
The FDA has cleared InnoCare Pharma’s investigational new drug application for ICP-332, according to a press release.
FDA approves Adbry autoinjector for atopic dermatitis
The FDA has approved a single-dose autoinjector for Adbry, LEO Pharma announced in a press release.
Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
VIDEO: Topical treatments may be effective against moderate to severe atopic dermatitis
In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.
Atopic dermatitis may be linked to inflammatory bowel disease
An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.